Form 4: Apyx Medical Corp Director Baylor-Henry Acquires Stock Options

Director Minnie Baylor-Henry acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.

Summary

• Minnie Baylor-Henry, a director of Apyx Medical Corp, acquired 17,000 stock options on August 8, 2024.
• The options have an exercise price of $1.02.
• The options were issued as part of the Issuer's Director Compensation Program.
• The options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the date of grant.
• The options expire on August 8, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard director compensation practice. The acquisition of stock options by a director is generally viewed positively, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Director compensation through stock options is a common practice in publicly traded companies to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages vary widely across the medical device industry.
• Stock options are a typical component, often vesting over a period of one to three years.
• The specific number of options granted depends on factors such as company size, performance, and director responsibilities.
• Comparing Apyx Medical's director compensation to companies like Stryker, Medtronic, or Boston Scientific would provide a broader context, but specific details of those packages are not available in this document.

Stakeholder Impact

• The granting of stock options to directors aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates